Mike Mensinger - 31 Jan 2025 Form 4 Insider Report for Beta Bionics, Inc. (BBNX)

Role
Chief Product Officer
Signature
/s/ Stephen Feider, Attorney-in-Fact
Issuer symbol
BBNX
Transactions as of
31 Jan 2025
Net transactions value
+$566,940
Form type
4
Filing time
03 Feb 2025, 20:30:15 UTC
Previous filing
29 Jan 2025
Next filing
03 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBNX Common Stock Conversion of derivative security +15,107 15,107 31 Jan 2025 Direct F1
transaction BBNX Common Stock Exercise of in-the-money or at-the-money derivative security $212 +10,575 +70% $0.0200 25,682 31 Jan 2025 Direct
transaction BBNX Common Stock Sale $221 -13 -0.05% $17.00 25,669 31 Jan 2025 Direct F2
transaction BBNX Common Stock Purchase $566,950 +33,350 +130% $17.00 59,019 31 Jan 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBNX Series D Preferred Stock Conversion of derivative security -15,107 -100% 0 31 Jan 2025 Common Stock 15,107 Direct F1
transaction BBNX Class B Common Stock Warrant (right to buy) Conversion of derivative security $0 +10,575 $0.000000 10,575 31 Jan 2025 Common Stock 10,575 $0.0200 Direct F4
transaction BBNX Class B Common Stock Warrant (right to buy) Exercise of in-the-money or at-the-money derivative security $0 -10,575 -100% $0.000000 0 31 Jan 2025 Common Stock 10,575 $0.0200 Direct F4
transaction BBNX Employee Stock Option (right to buy) Award $0 +236,553 $0.000000 236,553 31 Jan 2025 Common Stock 236,553 $5.10 Direct F5, F6
transaction BBNX Employee Stock Option (right to buy) Award $0 +110,278 $0.000000 110,278 31 Jan 2025 Common Stock 110,278 $17.00 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date.
F2 On January 31, 2025, the reporting person exercised a warrant to purchase 10,575 shares of Issuer's common stock for $0.02 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in withholding of 13 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 10,562 shares.
F3 The shares were purchased in the Issuer's initial public offering.
F4 Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this warrant was converted into an equal number of shares of Common Stock.
F5 One-fourth of the shares subject to this option shall vest one year after August 1, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.
F6 Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock.
F7 Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts.